Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Amplia Therapeutics ( (AU:ATX) ) has shared an announcement.
Amplia Therapeutics Limited announced the cessation of 5,626,000 securities due to the expiry of options without exercise or conversion. This development may impact the company’s capital structure and could influence investor perceptions regarding its financial strategies and future growth prospects.
The most recent analyst rating on (AU:ATX) stock is a Buy with a A$0.42 price target. To see the full list of analyst forecasts on Amplia Therapeutics stock, see the AU:ATX Stock Forecast page.
More about Amplia Therapeutics
Amplia Therapeutics Limited operates in the biotechnology industry, focusing on the development of therapeutic drugs. The company is engaged in creating innovative treatments aimed at addressing unmet medical needs, with a particular emphasis on cancer therapies.
Average Trading Volume: 3,754,086
Technical Sentiment Signal: Buy
Current Market Cap: A$89.79M
For detailed information about ATX stock, go to TipRanks’ Stock Analysis page.